Sodium Tanshinone II A Sulfonate for Coronary Heart Disease: A Systematic Review of Randomized Controlled Trials

[1]  Jie Ren,et al.  Salvia miltiorrhiza in Treating Cardiovascular Diseases: A Review on Its Pharmacological and Clinical Applications , 2019, Front. Pharmacol..

[2]  Wei Wang,et al.  Tanshinone IIA Restores Dynamic Balance of Autophagosome/Autolysosome in Doxorubicin-Induced Cardiotoxicity via Targeting Beclin1/LAMP1 , 2019, Cancers.

[3]  Jie Wang,et al.  Bioactive Ingredients in Chinese Herbal Medicines That Target Non-coding RNAs: Promising New Choices for Disease Treatment , 2019, Front. Pharmacol..

[4]  Jiarui Wu,et al.  Sodium Tanshinone II A Sulfonate Injection as Adjuvant Treatment for Unstable Angina Pectoris: A Meta-Analysis of 17 Randomized Controlled Trials , 2018, Chinese Journal of Integrative Medicine.

[5]  Yang Jiao,et al.  Sodium tanshinone IIA sulfate adjunct therapy reduces high-sensitivity C-reactive protein level in coronary artery disease patients: a randomized controlled trial , 2017, Scientific Reports.

[6]  P. Libby,et al.  Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial , 2017, The Lancet.

[7]  A. Keech,et al.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease , 2017, The New England journal of medicine.

[8]  J. Rich.  Cancer stem cells: master gatekeepers and regulators of cancer growth and metastasis Introduction , 2016, Medicine.

[9]  Hao Xu,et al.  Anti-Inflammatory and Immunomodulatory Mechanism of Tanshinone IIA for Atherosclerosis , 2014, Evidence-based complementary and alternative medicine : eCAM.

[10]  Nathan D. Wong,et al.  Epidemiological studies of CHD and the evolution of preventive cardiology , 2014, Nature Reviews Cardiology.

[11]  V. Kadirkamanathan,et al.  A Zebrafish Compound Screen Reveals Modulation of Neutrophil Reverse Migration as an Anti-Inflammatory Mechanism , 2014, Science Translational Medicine.

[12]  W. Yao,et al.  A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of qili qiangxin capsules in patients with chronic heart failure. , 2013, Journal of the American College of Cardiology.

[13]  Hao Xu,et al.  Tanshinone IIA: A Promising Natural Cardioprotective Agent , 2012, Evidence-based complementary and alternative medicine : eCAM.

[14]  D. Capuzzi,et al.  Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. , 2008, The American journal of cardiology.

[15]  Claudio Napoli,et al.  Rethinking primary prevention of atherosclerosis-related diseases. , 2006, Circulation.

[16]  Da-zhuo Shi,et al.  XS0601 reduces the incidence of restenosis: a prospective study of 335 patients undergoing percutaneous coronary intervention in China. , 2006, Chinese medical journal.

[17]  Jiarui Wu,et al.  A systematic review and meta-analysis , 2016 .

[18]  Liang Jin-chen.  Influence of Tanshinone IIA Sulfonate Injection Combined with Simvastatin on Inflammatory Factor in Patients with Coronary Heart Disease , 2015 .

[19]  Zhang Xinr.  The Impact of Tan Treatment on Haemodynamics and Blood Lipid of Acute Myocardial Infarction Patients , 2014 .

[20]  W. Qu.  Effects of tanshinone II on clinical symptoms and vascular aging factor in angina pectoris of coronary heart disease patients , 2014 .

[21]  J. Higgins,et al.  Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration , 2013 .

[22]  Wang Cun-xuan.  Effects of sodium tanshinone I A sulfonate on arrhythmia induced by myocardial ischemia-reperfusion , 2011 .

[23]  Tang Ji-wen.  The effect and clinical significance of tanshinone injection on plasma NT-proBNP in acute myocardial infarction , 2009 .

[24]  Cochrane Handbook for Systematic Reviews of Interventions Edited by Julian P. T. Higgins & , 2006 .